

LIST OF TABLES

Table No.	Table Captions	Page No.
1.1	Chemical structures, mechanism, and adverse effects of USFDA approved drugs for the treatment of AD.	11
5.1	Glide score, interacting residues, and MM-GBSA ΔG binding free energy of identified hits (SEW06622, AW01119, and PD00698) against AChE and BACE-1.	60
5.2	Cholinesterases (hAChE and hBChE) and hBACE-1 inhibition activity and selectivity index of compounds (Series I).	81
5.3	Propidium iodide displacement and predicted BBB permeability (Series I).	85
5.4	Pharmacokinetic evaluation after an oral administration of S_I4j (10 mg/kg, p.o.)	94
5.5	Cholinesterases (hAChE and hBChE) and hBACE-1 inhibition activity and selectivity index of compounds (Series II-V).	118
5.6	Propidium iodide displacement and predicted BBB permeability (Series II-V).	123
5.7	Pharmacokinetic evaluation after an oral administration of S_{III}10g (10 mg/kg, p.o.)	133